Cerevance is set to present Phase 2 data for Solengepras (CVN424), a novel non-dopaminergic GPR6 inhibitor, at the upcoming American Academy of Neurology 2026 Annual Meeting. The findings from two Phase 2 trials indicate that Solengepras significantly reduces daily OFF time and enhances sleep-related symptoms in patients. These results will be showcased in poster presentations by Dr. Robert Hauser and Dr. Harini Sarva on April 21.

The significance of these findings lies in Solengepras’ potential to address motor fluctuations in patients with Parkinson’s disease without directly modulating dopamine signaling. By functioning as an adjunct to levodopa, the current gold standard for managing Parkinson’s symptoms, Solengepras aims to improve both motor and non-motor functions. The ongoing Phase 3 ARISE trial, which will enroll approximately 330 patients aged 30 and older, seeks to validate these results further. The primary endpoint focuses on the change in average daily OFF time from baseline to week 12, particularly for the 150 mg dosage compared to placebo.

The implications of this research could be substantial for the field of aging and neurodegenerative diseases. If Solengepras demonstrates efficacy in the ARISE trial, it could shift current paradigms in Parkinson’s treatment strategies, potentially leading to a new class of therapies that manage symptoms without the complications associated with traditional dopaminergic treatments. This advancement may accelerate drug development timelines for similar non-dopaminergic approaches, fostering a broader exploration of therapeutic avenues in age-related motor disorders.

Source: longevity.technology